Particulate dermal matrix as an injectable soft tissue replacement material.

Autor: Griffey S; LifeCell Corporation, Branchburg, New Jersey 08876, USA. sgriffey@lifecell.com, Schwade ND, Wright CG
Jazyk: angličtina
Zdroj: Journal of biomedical materials research [J Biomed Mater Res] 2001; Vol. 58 (1), pp. 10-5.
DOI: 10.1002/1097-4636(2001)58:1<10::aid-jbm20>3.0.co;2-e
Abstrakt: Products currently used as injectable soft tissue replacement materials in the dermatologic, plastic and reconstructive, and urological fields exhibit several shortfalls including reactivity, migration, rapid degradation, and necessity of a donor site. This study examines the feasibility of providing a particulate acellular human dermal matrix for injection as a soft tissue replacement material that addresses many of these issues. Animal feasibility studies tested differences in implant performance related to processing techniques, matrix concentration, and volume of the collagen matrix to be injected. Results demonstrated that processing techniques that involve shearing and tearing of the dermal collagen matrix resulted in frayed and damaged collagen bundles and led to rapid resorption or loss of the implant, when injected subcutaneously in a rat model. Processing the collagen matrix in liquid nitrogen resulted in less damage to the collagen matrix and exhibited longer persistence, when compared to the damaged collagen matrix. This particulate matrix also exhibits rapid repopulation by host cells that should enhance revascularization and remodeling. The particulate nature of this processed dermal matrix allows for easy delivery of concentrations up to 330 mg/mL, which exceeds that of other currently used products. This increased concentration should allow for decreased need of "overcorrection" and repeated injections.
(Copyright 2000 John Wiley & Sons, Inc. Biomed Mater Res (Appl Biomater) 58: 10-15, 2001)
Databáze: MEDLINE
Externí odkaz: